Drug-Drug Interactions Potential of Icariin and Its Intestinal Metabolites via Inhibition of Intestinal UDP-Glucuronosyltransferases

被引:24
作者
Cao, Yun-Feng [1 ,2 ]
He, Rong-Rong [3 ]
Cao, Jun [4 ]
Chen, Jian-Xing [2 ]
Huang, Ting [2 ]
Liu, Yong [1 ]
机构
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Lab Pharmaceut Resource Discovery, Dalian 116023, Peoples R China
[2] Shanghai Inst Planned Parenthood Res, Shanghai Engineer & Technol Res Ctr Reprod Hlth D, Key Lab Contracept & Devices Res NPFPC, Shanghai 200032, Peoples R China
[3] Jinan Univ, Coll Pharm, Guangzhou 510632, Guangdong, Peoples R China
[4] Dalian Med Univ, Occupat & Environm Hlth Dept, Dalian 116044, Peoples R China
基金
中国国家自然科学基金;
关键词
IN-VITRO; GINSENOSIDE; GLUCURONIDATION; EXPRESSION; PARAMETERS; MEDICINES; SUBSTRATE; RESPONSES; PROBES;
D O I
10.1155/2012/395912
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Icariin is known as an indicative constituent of the Epimedium genus, which has been commonly used in Chinese herbal medicine to enhance treat impotence and improve sexual function, as well as for several other indications for over 2000 years. In this study, we aimed to investigate the effects of icariin and its intestinal metabolites on the activities of human UDP-glucuronosyltransferase (UGT) activities. Using a panel of recombinant human UGT isoforms, we found that icariin exhibited potent inhibition against UGT1A3. It is interesting that the intestinal metabolites of icariin exhibited a different inhibition profile compared with icariin. Different from icariin, icariside II was a potent inhibitor of UGT1A4, UGT1A7, UGT1A9, and UGT2B7, and icaritin was a potent inhibitor of UGT1A7 and UGT1A9. The potential for drug interactions in vivo was also quantitatively predicted and compared. The quantitative prediction of risks indicated that in vivo inhibition against intestinal UGT1A3, UGT1A4, and UGT1A7 would likely occur after oral administration of icariin products.
引用
收藏
页数:8
相关论文
共 32 条
  • [1] The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    Bjornsson, TD
    Callaghan, JT
    Einolf, HJ
    Fischer, V
    Gan, L
    Grimm, S
    Kao, J
    King, SP
    Miwa, G
    Ni, L
    Kumar, G
    McLeod, J
    Obach, RS
    Roberts, S
    Roe, A
    Shah, A
    Snikeris, F
    Sullivan, JT
    Tweedie, D
    Vega, JM
    Walsh, J
    Wrighton, SA
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) : 815 - 832
  • [2] [蔡垠 CAI Yin], 2009, [中国药学杂志, Chinese Pharmaceutical Journal], V44, P985
  • [3] Copeland RA, 2000, ENZYMES PRACTICAL IN
  • [4] PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS
    DAVIES, B
    MORRIS, T
    [J]. PHARMACEUTICAL RESEARCH, 1993, 10 (07) : 1093 - 1095
  • [5] Proof of the mysterious efficacy of ginseng: Basic and clinical trials: Metabolic activation of ginsenoside: Deglycosylation by intestinal bacteria and esterification with fatty acid
    Hasegawa, H
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 95 (02) : 153 - 157
  • [6] PHASE II DRUG METABOLIZING ENZYMES
    Jancova, Petra
    Anzenbacher, Pavel
    Anzenbacherova, Eva
    [J]. BIOMEDICAL PAPERS-OLOMOUC, 2010, 154 (02): : 103 - 116
  • [7] UDP-glucuronosyltransferases and clinical drug-drug interactions
    Kiang, TKL
    Ensom, MHH
    Chang, TKH
    [J]. PHARMACOLOGY & THERAPEUTICS, 2005, 106 (01) : 97 - 132
  • [8] Effects of the aqueous extract of Epimedii Herba on the antibody responses in mice
    Kim, JH
    Mun, YJ
    Im, SJ
    Han, JH
    Lee, HS
    Woo, WH
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (05) : 935 - 944
  • [9] Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba
    Liu, KH
    Kim, MJ
    Jeon, BH
    Shon, JH
    Cha, IJ
    Cho, KH
    Lee, SS
    Shin, JG
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2006, 31 (01) : 83 - 91
  • [10] Influence of ginsenoside Rh1 and F1 on human cytochrome P450 enzymes
    Liu, Y
    Ma, H
    Zhang, JW
    Deng, MC
    Yang, L
    [J]. PLANTA MEDICA, 2006, 72 (02) : 126 - 131